Full text is available at the source.
The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect
Gut bacteria may help immune therapy work better against tumors
AI simplified
Abstract
Immune-checkpoint inhibitors (ICIs) have improved survival in cancer patients, but durable benefits are limited.
- A limited number of patients experience sustained benefits from ICIs.
- The gut microbiome plays a significant role in influencing immune responses.
- There is potential for the gut microbiome to predict responses to ICI treatment.
- Mechanistic analyses and clinical trials suggest a relationship between gut microbiome and ICI efficacy.
- Research is ongoing to develop strategies leveraging the gut microbiome to improve ICI treatment outcomes.
AI simplified